Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, protein quality control and cellular health, whose failure could be the leading ...

Recently, the company announced a collaboration with the Charcot–Marie–Tooth Association ... first-in-class treatment for peripheral neuropathies, which affect many millions of people ...

In light of those characteristics, Cellatoz is applying NRPCs, in the form of CLZ-2002, to the treatment of Charcot–Marie–Tooth (CMT) type 1A disease and other health conditions caused by ...

The FDA's ODD for the therapy follows a previous grant for the treatment of generalised ... "FDA grants ODD to NMD Pharma’s Charcot-Marie-Tooth disease therapy" was originally created and ...

French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.

This novel treatment approach has resulted in clinical evidence of CIC-1 inhibition in myasthenia gravis and preclinical evidence in spinal muscular atrophy, Charcot-Marie Tooth disease and sarcopenia ...

With a history of spinal injury and having not undergone a surgical stabilization, a syrinx was suspected. A magnetic resonance imaging (MRI) study of the patient's cervical and thoracic spine was ...

Neuropathic osteoarthropathy, otherwise known as Charcot neuroarthropathy, is a chronic, degenerative arthropathy and is associated with decreased sensory innervation. Numerous causes of this ...